CoChat

Adeno-Associated Vector (Type 8)-Mediated Expression of Soluble Flt-1 Efficiently Inhibits Neovascularization in a Murine Choroidal Neovascularization Model

Igarashi, Tsutomu, Miyake, Koichi, Masuda, Ikuya, Takahashi, Hiroshi, Shimada, Takashi · 2010 · Human Gene Therapy
Cited by 40

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

To assess the feasibility of a gene therapeutic approach to treating choroidal neovascularization (CNV), we generated a recombinant adeno-associated viral (AAV) vector (type 8) encoding soluble Flt-1 (AAV-sflt-1), and determined its ability to inhibit angiogenesis. When we treated human umbilical vein endothelial cells (HUVECs) with the supernatant of cells transduced with AAV-sflt-1 or AAV-EGFP (control), we found that tube formation was significantly inhibited by the former but not the latter (area: 25,121 +/- 557 vs. 68,628 +/- 1357 pixels [p < 0.01]; length: 4811 +/- 246 vs. 10,894 +/- 297 pixels [p < 0.01]). CNV was induced in C57BL/6 mice by making four separate choroidal burns around the optic nerve in each eye, using a diode laser. Thereafter, 2 microl (5 x 10(11) vector genomes/ml) of AAV-sflt-1 (n = 11) or control AAV-LacZ (n = 12) was injected into the subretinal space, and 2 weeks later the eyes were removed for flatmount analysis of CNV surface area. Notably, subretinal delivery of AAV-sflt-1 significantly diminished CNV at the laser lesions, as compared with AAV-LacZ (555 +/- 304 vs. 1470 +/- 1000 microm(2); p = 0.007). These results suggest that there was diffusion of the secreted sFlt-1 across the retina and that long-term suppression of CNV is possible through the use of stable rAAV-mediated sflt-1 expression. In vivo gene therapy thus appears to be a feasible approach to the clinical management of CNV in conditions such as age-related macular degeneration.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1089/hum.2009.153

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • Causes and Prevalence of Visual Impairment Among Adults in the UnitedStates

    (2004) · Archives of Ophthalmology · doi:10.1001/archopht.122.4.477 · Cited by 2,616 · cited 1×

    “…Fine, 1981; Sickenberg et al. , 2000), and in particular age-related macular degeneration (AMD) (Young, 1987; Starr et al. , 1998), which is the most frequent cause of visual impairment in individuals over the age of 40 years in developed countries (Congdon et al. , 2004; Coleman et al. , 2008).”
  • Pegaptanib for neovascular age-related macular degeneration

    Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337 · cited 1×

    “…ligand showing at least 10-fold higher affinity for Flt-1 than Flk-1 = KDR. Clinically, inhibition of the VEGF pathway, using a VEGF aptamer or an anti-VEGF antibody, effectively suppresses its CNV-related activity (Gragoudas et al. , 2004; Kaiser, 2006; Ng et al. , 2006; Rosenfeld et al. , 2006).”
  • Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis

    Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145 · cited 1×

    “These three trials are similar in that they all investigated the efficacy of using AAV type 2 vector-mediated gene transfer to treat Leber’s congenital amaurosis, a severe inherited form of early-onset retinal degeneration (Maguire et al. , 2008).”
  • Age-related macular degeneration

    Coleman, H. R., Chan, C.-C., Ferris, F. L., & Chew, E. Y. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61759-6 · Cited by 542

Cited by

See all 40

Metadata

Authors
Igarashi, T., Miyake, K., Masuda, I., Takahashi, H., & Shimada, T.
Venue
Human Gene Therapy
Published
2010-05
Volume
21
Issue
5
Pages
631-637
ISSN
  • 1043-0342 (ISSN-L)
  • 1557-7422
OpenAlex
W2081364421
Cited by
40
References
4
FWCI
4.29
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.